Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AS-202
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $580.0 million
Deal Type : Licensing Agreement
AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics
Details : Under the terms of the agreement, Takeda will receive an exclusive, worldwide license to AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Product Name : AS-202
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : AS-202
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $580.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AS-202
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : US Department of Defense
Deal Size : $1.0 million
Deal Type : Funding
AcuraStem Awarded $1M DOD Grant to Advance AS-202 Drug Development Candidate for ALS
Details : The CDMRP award nomination underscores the significance of AcuraStem’s drug candidate AS-202. AcuraStem’s most advanced therapeutic candidate, AS-202, lowers levels of the lipid kinase PIKFYVE.
Product Name : AS-202
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
May 25, 2021
Lead Product(s) : AS-202
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : US Department of Defense
Deal Size : $1.0 million
Deal Type : Funding